Hi vrs37, looking at the conditions attached to the CE mark I'd be surprised if they get many other sales. The CE limits the use of the product to use in combination with gemcitabine only as a chemotherapy. Gemcitabine alone is a very outdated treatment for this cancer. There are other, more effective chemotherapeutic agents available now, that are likely also reimbursed. So why would an oncologist suggest a patient pay out of their own pocket for a therapy that they know they can get equal or better results from that they don't have to completely cover the cost of.
Ann: OncoSil receives Swiss regulatory approval, page-47
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.32M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $23.68K | 4.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 23118264 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5200224 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |